American Century Companies Inc Blueprint Medicines Corp Transaction History

American Century Companies Inc

$168 Billion
Q4 2024

A detailed history of American Century Companies Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, American Century Companies Inc holds 839,203 shares of BPMC stock, worth $79.2 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

839,203

Previous 815,071 2.96%

Holding current value

$79.2 Million

Previous $75.4 Million 2.87%

% of portfolio

0.04%

Previous 0.05%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	BUY	$82.48 - $101.39 $1.99 Million - $2.45 Million	24,132 Added 2.96%	839,203 $73.2 Million
Q3 2024 Nov 12, 2024	BUY	$84.1 - $120.5 $1.04 Million - $1.49 Million	12,338 Added 1.54%	815,071 $75.4 Million
Q2 2024 Aug 07, 2024	BUY	$85.18 - $108.78 $2.78 Million - $3.55 Million	32,600 Added 4.23%	802,733 $86.5 Million
Q1 2024 May 14, 2024	BUY	$73.17 - $99.79 $4.27 Million - $5.83 Million	58,399 Added 8.21%	770,133 $73.1 Million
Q4 2023 Feb 13, 2024	BUY	$43.96 - $92.84 $31.3 Million - $66.1 Million	711,734 New	711,734 $65.7 Million
Q3 2023 Nov 13, 2023	BUY	$46.9 - $66.0 $1.56 Million - $2.19 Million	33,243 Added 5.21%	670,972 $33.7 Million
Q2 2023 Aug 14, 2023	BUY	$42.2 - $66.37 $970,937 - $1.53 Million	23,008 Added 3.74%	637,729 $40.3 Million
Q1 2023 May 11, 2023	SELL	$37.97 - $50.0 $59,650 - $78,550	-1,571 Reduced 0.25%	614,721 $27.7 Million
Q4 2022 Feb 13, 2023	BUY	$41.06 - $66.48 $247,838 - $401,273	6,036 Added 0.99%	616,292 $27 Million
Q3 2022 Nov 14, 2022	SELL	$49.93 - $77.7 $1.22 Million - $1.9 Million	-24,439 Reduced 3.85%	610,256 $40.2 Million
Q2 2022 Aug 12, 2022	SELL	$45.23 - $70.15 $5.52 Million - $8.56 Million	-122,030 Reduced 16.13%	634,695 $32.1 Million
Q1 2022 May 11, 2022	SELL	$54.1 - $110.08 $5.85 Million - $11.9 Million	-108,056 Reduced 12.5%	756,725 $48.3 Million
Q4 2021 Feb 07, 2022	SELL	$94.25 - $115.99 $41,752 - $51,383	-443 Reduced 0.05%	864,781 $92.6 Million
Q3 2021 Nov 10, 2021	BUY	$80.98 - $109.47 $5.13 Million - $6.93 Million	63,302 Added 7.89%	865,224 $89 Million
Q2 2021 Aug 05, 2021	SELL	$82.78 - $101.0 $2.54 Million - $3.09 Million	-30,640 Reduced 3.68%	801,922 $70.5 Million
Q1 2021 May 14, 2021	BUY	$90.71 - $108.28 $7.39 Million - $8.82 Million	81,466 Added 10.85%	832,562 $81 Million
Q4 2020 Feb 12, 2021	BUY	$92.08 - $124.48 $1.39 Million - $1.87 Million	15,057 Added 2.05%	751,096 $84.2 Million
Q3 2020 Nov 13, 2020	BUY	$66.45 - $92.7 $2.22 Million - $3.1 Million	33,460 Added 4.76%	736,039 $68.2 Million
Q2 2020 Aug 13, 2020	BUY	$57.09 - $79.27 $10.4 Million - $14.5 Million	182,618 Added 35.12%	702,579 $54.8 Million
Q1 2020 May 14, 2020	SELL	$48.11 - $82.22 $1.2 Million - $2.04 Million	-24,866 Reduced 4.56%	519,961 $30.4 Million
Q4 2019 Feb 12, 2020	BUY	$66.73 - $82.59 $9.39 Million - $11.6 Million	140,717 Added 34.82%	544,827 $43.6 Million
Q3 2019 Nov 13, 2019	BUY	$72.9 - $101.41 $288,975 - $401,989	3,964 Added 0.99%	404,110 $29.7 Million
Q2 2019 Aug 14, 2019	BUY	$73.54 - $97.8 $4.82 Million - $6.4 Million	65,488 Added 19.57%	400,146 $37.7 Million
Q1 2019 May 14, 2019	BUY	$48.7 - $86.6 $3.07 Million - $5.46 Million	63,098 Added 23.24%	334,658 $0
Q4 2018 Feb 13, 2019	BUY	$45.57 - $74.26 $8.51 Million - $13.9 Million	186,852 Added 220.58%	271,560 $14.6 Million
Q3 2018 Nov 02, 2018	BUY	$58.91 - $78.32 $1.52 Million - $2.01 Million	25,726 Added 43.62%	84,708 $6.61 Million
Q2 2018 Aug 08, 2018	BUY	$60.96 - $101.18 $987,369 - $1.64 Million	16,197 Added 37.86%	58,982 $3.74 Million
Q1 2018 May 03, 2018	BUY	$73.28 - $102.95 $3.14 Million - $4.4 Million	42,785 New	42,785 $3.92 Million

Others Institutions Holding BPMC

# of Institutions

380

Shares Held

65.9M

Call Options Held

1.6M

Put Options Held

1.41M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.63B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.

Account

American Century Companies Inc Blueprint Medicines Corp Transaction History